We then employed combinations of transgenic IFNγ‐deficient mice and IL‐10‐deficient MSCs to selectively probe the molecular mechanisms behind pFUS improving MSC therapy for AKI in vivo. This evidence concerns the gene IL10 and acute kidney injury.